Contact Us
Drug Search Results
More Filters [+]

Odalasvir

Alternative Names: odalasvir, ach-3102, ach-0143102
Latest Update: 2023-08-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: HCV-NS5A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Odalasvir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C

Phase 1: Healthy Volunteers|Kidney Diseases|Communicable Diseases|Hepatitis C, Chronic|Hepatitis A|Hepatitis C

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AL-335-604

P2

Completed

Hepatitis C, Chronic

2018-05-11

AL-335-604

P2

Completed

Hepatitis C, Chronic

2018-05-11

2016-002845-46

P2

Completed

Hepatitis C, Chronic

2018-05-11

CR108264

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2018-05-07

CR108264

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2018-05-07

CR108242

P1

Completed

Kidney Diseases

2018-04-09

22%

Recent News Events

Date

Type

Title

11/01/2020

PubMed

 Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review.

06/01/2020

PubMed

 JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

05/25/2020

News Article

 Global Anti-Infective Drugs Market Report (2020 to 2030) - COVID-19 Implications and Growth

05/22/2020

News Article

 Impact of COVID-19 on the Worldwide Anti-Infective Drugs Industry to 2030 - Benchmark Performance Against Key Competitors - ResearchAndMarkets.com

07/25/2019

News Article

 Global Anti-Infective Drugs Market Report 2019 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions